Redustim device for reduction of abdominal obesity

Safety and efficacy assessment of Redustim device, for reduction of abdominal obesity in healthy volunteers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190210042676N3

Enrollment

Registered

2019-07-28

Start date

2019-07-12

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

local obesity.

Interventions

12 treatment sessions each session 45 minutes, using Redustim slimming device (product of COSMOSOFT, company. France) on abdominal area, hip and arms. Associating alternate low frequency electromagn

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: People who suffering from abdominal obesity Signing the consent form for participation in the study Women or men between 18 to 60

Exclusion criteria

Exclusion criteria: Uncontrolled hypertention Currently pregnant or lactating Deep vascular tumors Endocrine disorders

Design outcomes

Primary

Measure	Time frame
Abdominal size. Timepoint: Before starting treatment, the second week and the 4th week after treatment. Method of measurement: Centimeter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026